Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: The effects of network structure

Journal of the Royal Society Interface

Volumn 8, Issue 63, 2011, Pages 1510-1520

  Mills, H L ^a   Cohen, T ^b,c   Colijn, C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Clustering; Co infection; Epidemics; Infectious disease; Mathematical model; Re infection

Indexed keywords

DRUG THERAPY; HEALTH RISKS; HYDRAZINE; MATHEMATICAL MODELS; POPULATION STATISTICS;

CLUSTERING; CO-INFECTIONS; EPIDEMICS; INFECTIOUS DISEASE; RE-INFECTION;

DISEASE CONTROL;

ISONIAZID;

ARTICLE; CLUSTER ANALYSIS; DISEASE TRANSMISSION; ENDEMIC DISEASE; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; POPULATION STRUCTURE; POSTPRIMARY TUBERCULOSIS; SIMULATION; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 80052204962     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2011.0160     Document Type: Article

References (51)

1. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C. & Dye, C. 2003 The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Int. Med. 163, 1009-1021. (doi:10.1001/archinte.163.9.1009)
2. UNAIDS. 2008 Report on the global AIDS epidemic, August 2008. See http://data.unaids.org/pub/GlobalReport/2008/jc1510-2008globalreport-en.pdf.
3. World Health Organization. 2009 Global tuberculosis control: a short update to the 2009 report, March. See http://whqlibdoc.who.int/publications/ 2009/9789241598866-eng.pdf.
4. Lawn, S. D., Wood, R. & Wilkinson, R. J. 2011 Changing concepts of 'latent tuberculosis infection' in patients living with HIV infection. Clin. Dev. Immunol. 2011, 980594 (doi:10.1155/2011/980594)
5. World Health Organization. 2008 WHO Three I's Meeting, April 2008. Report of a joint WHO HIV/AIDS and TB Department meeting, Geneva, Switzerland, 2-4 April 2008. See http://www.who.int/hiv/pub/meetingreports/WHO-3Is-meeting- report.pdf.
6. World Health Organization. 2009 Isoniazid preventive therapy (IPT) for people living with HIV, Consensus statement of the Core Group of the TB/HIV Working Group of the Stop TB Partnership. See http://www.who.int/tb/features- archive/ipt-statement-tbhiv-coregroup.pdf.
7. Samandari, T. et al. 2010 Randomized, placebo-controlled trial of 6 vs 36 months isoniazid TB preventive therapy for HIV-infected adults in Botswana. In 17th Conf. on Retroviruses and Opportunistic Infections; San Francisco, CA, USA, 16-19 February 2010, Abstract 104LB.
8. Akolo, C., Adetifa, I., Shepperd, S. & Volmink, J. 2010 Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 1, CD000171. (doi:10.1002/14651858.CD000171.pub3)
9. Smieja, M., Marchetti, C., Cook, D. & Smaill, F. M. 1999 Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 1, CD001363. (doi:10.1002/14651858.cd001363)
10. Cohen, T., Lipsitch, M., Walensky, R. P. & Murray, M. 2006 Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc. Natl Acad. Sci. USA 103, 7042-7047. (doi:10.1073/pnas.0600349103)
11. Long, E. F., Vaidya, N. K. & Brandeau, M. L. 2008 Controlling co-epidemics: analysis of HIV and tuberculosis infection dynamics. Oper. Res. 56, 1366-1381. (doi:10.1287/opre.1080.0571)
12. Bhunu, C. P., Garira, W. & Mukandavire, Z. 2009 Modeling HIV/AIDS and tuberculosis coinfection. Bull. Math. Biol. 71, 1745-1780. (doi:10.1007/s11538- 009-9423-9)
13. Mossong, J. et al. 2008 Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5, e74. (doi:10.1371/journal.pmed. 0050074)
14. Hens, N., Goeyvaerts, N., Aerts, M., Shkedy, Z., Van Damme, P. & Beutels, P. 2009 Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium. BMC Infect. Dis. 9, 5. (doi:10.1186/1471-2334-9-5)
15. Keeling, M. J. & Eames, K. T. D. 2005 Networks and epidemic models. J. R. Soc. Interface 2, 295-307. (doi:10.1098/rsif.2005.0051)
16. Touray, K., Adetifa, I. M., Jallow, A., Rigby, J., Jeffries, D., Cheung, Y. B., Donkor, S., Adegbola, R. A. & Hill, P. C. 2010 Spatial analysis of tuberculosis in an Urban West African setting: is there evidence of clustering? Trop. Med. Int. Health 15, 664-672. (doi:10.1111/j.1365-3156.2010.02533.x)
17. Gardy, J. L. et al. 2011 Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N. Engl. J. Med. 364, 730-739.
18. Read, J. M. & Keeling, M. J. 2003 Disease evolution on networks: the role of contact structure. Proc. R. Soc. Lond. B 270, 699-708. (doi:10.1098/rspb.2002.2305)
19. Newman, M. E. J. 2002 Spread of epidemic disease on networks. Phys. Rev. E 66, 016128. (doi:10.1103/PhysRevE.66.016128)
20. Liljeros, F., Edling, C. R., Amaral, L. A. N., Stanley, H. E. & Åberg, Y. 2001 The web of human sexual contacts. Nature 411, 907-908. (doi:10.1038/35082140)
21. Cohen, T., Colijn, C., Finklea, B. & Murray, M. 2007 Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J. R. Soc. Interface 4, 523-531. (doi:10.1098/rsif.2006.0193)
22. World Health Organization. 2009 AIDS epidemic update. See http://data.unaids.org/pub/Report/2009/JC1700-Epi-Update-2009-en.pdf.
23. Vynnycky, E. & Fine, P. E. M. 1997 The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119, 183-201. (doi:10.1017/S0950268897007917)
24. Springett, V. H. 1971 Ten-year results during the introduction of chemotherapy for tuberculosis. Tubercle 52, 73-87.
25. Enarson, D. A. & Rouillon, A. 1998 The epidemiological basis of tuberculosis control. In Clinical tuberculosis, 2nd edn (ed. P. D. O. Davies), pp. 35-52. London, UK: Chapman and Hall Medical.
26. Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. 1998 Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet Infect. Dis. 352, 1886-1891.
27. World Health Organization. 2006 WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children, August 2006. See http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf.
28. Ripley, B. D. 1976 The second-order analysis of stationary point processes. J. Appl. Probab. 13, 255-266. (doi:10.2307/3212829)
29. Newman, M. E. J. 2003 Properties of highly clustered networks. Phys. Rev. E 68, 026121. (doi:10.1103/PhysRevE.68.026121)
30. Dixon, P. M. 2002 Ripley's K function. Encycl. Environmetr. 3, 1796-1803.
31. Date, A. A., Vitoria, M., Granich, R., Banda, M., Fox, M. Y. & Gilks, C. 2010 Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull. World Health Organ. 88, 253-259. (doi:10.2471/BLT.09.066522)
32. Mosimaneotsile, B., Mathoma, A., Chengeta, B., Nyirenda, S., Agizew, T. B., Tedla, Z., Motsamai, O. I., Kilmarx, P. H., Wells, C. D. & Samandari, T. 2010 Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004-2006. J. Acquir. Immune Defic. Syndr. 54, 71-77.
33. Reid, M. J. A. & Shah, N. S. 2009 Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect. Dis. 9, 173-184. (doi:10.1016/S1473-3099(09)70043-x)
34. World Health Organization. 2010 Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings, December. See http://whqlibdoc.who.int/ publications/2011/9789241500708-eng.pdf.
35. Boughton, B. 2010 Two studies, 2 conclusions about duration of TB prevention therapy for HIV-infected patients. Medscape Medical News, February 2010 (online).
36. Swaminathan, S. et al. 2010 Efficacy of a 6-month vs a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. In 17th Conf. on Retroviruses and Opportunistic Infections; San Francisco, CA, USA, 16-19 February 2010, Abstract 103.
37. Chin, D. P., Crane, C. M., Diul, M. Y., Sun, S. J., Agraz, R., Taylor, S., Desmond, E. & Wise, F. 2000 Spread of Mycobacterium tuberculosis in a community implementing recommended elements of tuberculosis control. J. Am. Med. Assoc. 283, 2968-2974. (doi:10.1001/jama.283.22.2968)
38. Munch, Z., Van Lill, S. W. P., Booysen, C. N., Zietsman, H. L., Enarson, D. A. & Beyers, N. 2003 Tuberculosis transmission patterns in a high-incidence area: a spatial analysis. Int. J. Tuberc. Lung Dis. 7, 271-277.
39. KTD Eames. 2008 Modelling disease spread through random and regular contacts in clustered populations. Theor. Popul. Biol. 73, 104-111. (doi:10.1016/j.tpb.2007.09.007)
40. Miller, J. C. 2009 Spread of infectious disease through clustered populations. J. R. Soc. Interface 6, 1121-1134. (doi:10.1098/rsif.2008.0524)
41. Keeling, M. 2005 The implications of network structure for epidemic dynamics. Theor. Popul. Biol. 67, 1-8. (doi:10.1016/j.tpb.2004.08.002)
42. Salathé, M. & Jones, J. H. 2010 Dynamics and control of diseases in networks with community structure. PLoS Comput. Biol. 6, e1000736. (doi:10.1371/journal.pcbi.1000736)
43. Singh, J. A., Upshur, R. & Padayatchi, N. 2007 XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 4, e50. (doi:10.1371/journal.pmed.0040050)
44. Dye, C. 2009 Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat. Rev. Microbiol. 7, 81-87. (doi:10.1038/ nrmicro2048)
45. Jassal, M. & Bishai,W. R. 2009 Extensively drug-resistant tuberculosis. Lancet Infect. Dis. 9, 19-30. (doi:10.1016/S1473-3099(08)70260-3)
46. Cohen, T., Colijn, C. & Murray, M. 2008 Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proc. Natl Acad. Sci. USA 105, 16 302-16 307. (doi:10.1073/pnas.0808746105)
47. Colijn, C., Cohen, T. & Murray, M. 2009 Latent coinfection and the maintenance of strain diversity. Bull. Math. Biol. 71, 247-263. (doi:10.1007/s11538-008-9361-y)
48. Porco, T. C., Martin, J. N., Page-Shafer, K. A., Cheng, A., Charlebois, E., Grant, R. M. & Osmond, D. H. 2004 Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 18, 81-88. (doi:10.1097/00002030-200401020-00010)
49. Calmy, A., Pinoges, L., Szumilin, E., Zachariah, R., Ford, N. & Ferradini, L. 2006 Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20, 1163-1169. (doi:10.1097/01.aids.0000226957.79847.d6)
50. Salomon, J. A. & Hogan, D. R. 2008 Evaluating the impact of antiretroviral therapy on HIV transmission. AIDS 22, S149-S159. (doi:10.1097/01.aids.0000327636.82542.87)
51. Donnell, D. et al. 2010 Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet Infect. Dis. 375, 2092-2098. (doi:1016/S0140-6736(10)60705-2)